COVID-19 in India: Positive Cases: 3.625 Million, Recovery Rate 77%,

World | September 2, 2020, Wednesday // 14:27|  views


1. The number of positive cases has continued to increase and now stands at 3.625 million of which 785 thousand are active. However, the effective domestic response has led to significant improvements in their recovery rate, which has now increased to about 77%. The current fatality rate in India stands at 1.77%, which is much below the world average of 3.60%.

2. The rising number of cases may also be on account of enhanced testing being carried out by the Health Authorities across the country; over 1 million tests are being conducted every day. In addition, through Sero Survey testing methods, thousands of people are being tested in specific locations in the country to study the nature of the epidemiological spread.

3 Only eight States contribute to more than 75% of the cases and seven States contribute to overall deaths. As part of the comprehensive surveillance plan, Government has put in place an integrated command structure that extends to the district level to monitor and treat cases. Indian containment strategy seeks to limit the spread of virus in rural area. Government has significantly enhanced domestic capacity for fighting COVID-19 by regularly adding hospitals, beds and labs. Presently, there are about 69,265 hospitals with 19,29,692 beds, 96,485 ICUs and 48,242 ventilators.

4. India's domestic medical equipment manufacturing companies have also scaled up their production of PPEs, testing kits, ventilators, masks, including N-95. With export restrictions having been lifted through DGFT notifications, these items are now being exported abroad. 

5. Attention has now shifted to vaccine development in the country which is being monitored by the National Expert Group on Vaccine (NEGVAC). Three major Indian manufacturing companies are currently involved in vaccine trials: (i) Bharat Biotech in phase I and II with capacity to produce 50 million doses per month; (ii) Zydus-Cadila in phase I and II with capacity to produce 20 million doses; and (iii) Serum Institute in collaboration with Astrazeneca with capacity to produce 75 million doses per month. Collectively these three companies are likely to scale up production capacity to 300 million doses a month.

We need your support so can keep delivering news and information about Bulgaria! Thank you!